Logo_final_color.png
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
07 oct. 2024 07h00 HE | Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
Logo_final_color.png
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
16 sept. 2024 06h30 HE | Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Logo_final_color.png
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
25 juin 2024 08h07 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Regains Rights to CBX-12
06 févr. 2024 08h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium
10 oct. 2023 08h05 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
25 mai 2023 17h01 HE | Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Logo_final_color.png
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 avr. 2023 08h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
01 févr. 2023 08h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
15 déc. 2022 07h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Logo_final_color.png
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE | Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...